MannKind paid the first $.75 from the scPharma CVR. I have the cash in my account. As a reminder, we paid $.31 for the CVR. 11 months later, our return on that is 142%. If Furoscix sales meet guidance, we’ll collect an additional $.10 – $.25 in early 2027. The information we provide is … Read more
I’m still in Antigua, Guatemala where the weather is beautiful and I was woken up at 1am by the second earthquake in two weeks here. If one of you has upset a volcano, please apologize. The Federal Reserve kept the fed funds rate unchanged. Many expressed concern regarding the three dissenters who wanted a 25bp … Read more
As a reminder, DKI owned scPharma because we were positive on its product Furoscix as well as the likely approval of its autoinjector. We thought the company would be acquired. It was purchased last year by MannKind for cash and a contingent value right (CVR). For more details on the CVR, check out the post … Read more
According to Morgan Stanley, the cutoff date to tender your shares in the scPharma ($SCPH) acquisition is October 3rd, 3 days before the October 6th expiration date. Effectively, your options are to tender and receive $5.35 in cash plus the contingent value right (CVR) I’ve written about and explained in previous posts….or…..to sell your shares … Read more
MannKind has announced the tender date for scPharma is October 6th, 2025. If you want to own the contingent value right (CVR), you should keep your shares and tender them in the offer. If you don’t want to own the CVR, then you should sell your shares prior to October 6th. The documents filed … Read more
